Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis evaluate clinical outcomes from recombinant ADAMTS13 in thrombotic thrombocytopenic purpura, suggesting more research is needed.
rADAMTS13 significantly enhances ADAMTS13 activity but did not demonstrate a significant improvement in key clinical outcomes. These findings, based on two RCTs, are of moderate to low certainty per GRADE assessment. Larger trials are needed to confirm the clinical benefits of rADAMTS13.
No takes yet. Share an insight, caveat, or question.
Samad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: